Liver fibrosis: Our evolving understanding.
作者信息
Wells Rebecca G
机构信息
Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
出版信息
Clin Liver Dis (Hoboken). 2024 Jul 3;23(1):e0243. doi: 10.1097/CLD.0000000000000243. eCollection 2024 Jan-Jun.
Abstract
摘要
相似文献
1
Liver fibrosis: Our evolving understanding.
Clin Liver Dis (Hoboken). 2024 Jul 3;23(1):e0243. doi: 10.1097/CLD.0000000000000243. eCollection 2024 Jan-Jun.
2
Engineering and Monitoring 3D Cell Constructs with Time-Evolving Viscoelasticity for the Study of Liver Fibrosis In Vitro.
Bioengineering (Basel). 2021 Jul 27;8(8):106. doi: 10.3390/bioengineering8080106.
3
Evolving challenges in hepatic fibrosis.
Nat Rev Gastroenterol Hepatol. 2010 Aug;7(8):425-36. doi: 10.1038/nrgastro.2010.97. Epub 2010 Jun 29.
4
Evolving strategies for liver fibrosis staging: Non-invasive assessment.
World J Gastroenterol. 2017 Jan 14;23(2):191-196. doi: 10.3748/wjg.v23.i2.191.
5
Evolving Insights on Metabolism, Autophagy, and Epigenetics in Liver Myofibroblasts.
Front Physiol. 2016 Jun 1;7:191. doi: 10.3389/fphys.2016.00191. eCollection 2016.
6
Apoptosis and angiogenesis: an evolving mechanism for fibrosis.
FASEB J. 2013 Oct;27(10):3893-901. doi: 10.1096/fj.12-214189. Epub 2013 Jun 19.
7
Unravelling fibrosis using single-cell transcriptomics.
Curr Opin Pharmacol. 2019 Dec;49:71-75. doi: 10.1016/j.coph.2019.09.004. Epub 2019 Oct 25.
8
Evolving therapies for liver fibrosis.
J Clin Invest. 2013 May;123(5):1887-901. doi: 10.1172/JCI66028. Epub 2013 May 1.
9
Proteomics in liver fibrosis is more than meets the eye.
Eur J Gastroenterol Hepatol. 2008 May;20(5):450-64. doi: 10.1097/MEG.0b013e3282f4de92.
10
Efficacy and safety of anti-hepatic fibrosis drugs.
World J Gastroenterol. 2020 Nov 7;26(41):6304-6321. doi: 10.3748/wjg.v26.i41.6304.
本文引用的文献
1
Mechanobiology of portal hypertension.
JHEP Rep. 2023 Aug 2;5(11):100869. doi: 10.1016/j.jhepr.2023.100869. eCollection 2023 Nov.
2
The space of Mall confirmed in humans: A response to "Portal venous branches as an anatomic railroad for a gut-bile duct axis".
J Hepatol. 2024 Mar;80(3):e126-e127. doi: 10.1016/j.jhep.2023.09.029. Epub 2023 Oct 17.
3
The Origin and Fate of Liver Myofibroblasts.
Cell Mol Gastroenterol Hepatol. 2024;17(1):93-106. doi: 10.1016/j.jcmgh.2023.09.008. Epub 2023 Sep 22.
4
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
Hepatology. 2023 Dec 1;78(6):1966-1986. doi: 10.1097/HEP.0000000000000520. Epub 2023 Jun 24.
5
The gut-liver axis and gut microbiota in health and liver disease.
Nat Rev Microbiol. 2023 Nov;21(11):719-733. doi: 10.1038/s41579-023-00904-3. Epub 2023 Jun 14.
6
Changing epidemiology, global trends and implications for outcomes of NAFLD.
J Hepatol. 2023 Sep;79(3):842-852. doi: 10.1016/j.jhep.2023.04.036. Epub 2023 May 9.
7
Portal venous branches as an anatomic railroad for a gut-bile duct-axis.
J Hepatol. 2023 Aug;79(2):e82-e84. doi: 10.1016/j.jhep.2023.03.043. Epub 2023 Apr 11.
8
Regulators, functions, and mechanotransduction pathways of matrix stiffness in hepatic disease.
Front Physiol. 2023 Jan 12;14:1098129. doi: 10.3389/fphys.2023.1098129. eCollection 2023.
9
Mechanotransduction in the pathogenesis of non-alcoholic fatty liver disease.
J Hepatol. 2022 Dec;77(6):1642-1656. doi: 10.1016/j.jhep.2022.08.028. Epub 2022 Sep 5.
10
Understanding the cellular interactome of non-alcoholic fatty liver disease.
JHEP Rep. 2022 Jun 15;4(8):100524. doi: 10.1016/j.jhepr.2022.100524. eCollection 2022 Aug.
Zotero 插件